AIDS WEEKLY Plus - May - 2000Important note: Information in this article was accurate in May 2000. The state of the art may have changed since the publication date.
Click here to return to AIDS WEEKLY PLUS main menu

Education and Prevention: New International Program Will Focus on Global HIV/AIDS Issues

AIDSWEEKLY Plus; Monday, May 1, 2000
Prepared by AIDS Weekly editors from staff and other reports


NewsRx - The University of California at San Francisco AIDS Research Institute (ARI) is launching a new international program that will focus on stemming the worldwide HIV/AIDS epidemic.

Directed by Nancy Padian, MPH, PhD, a UCSF AIDS researcher widely recognized for major epidemiological studies on HIV and sexually transmitted diseases, the new UCSF ARI International Research Program will collaborate with health professionals throughout the UC system and in various global sites on projects related to AIDS policy, education, prevention, testing, and treatment.

The goal, according to Padian, is to build partnerships with researchers and institutions in other countries to work collaboratively to prevent HIV/AIDS. The program will be strongly linked to the Institute for Global Health - of UCSF and UC Berkeley and directed by Richard Feachem, PhD, Dsc - bringing together the already extensive international efforts in the Schools of Medicine, Nursing, Pharmacy, and Dentistry at UCSF, and the School of Public Health and other schools at UC Berkeley. The new program also will work to develop stronger ties with the San Francisco Department of Public Health on global HIV/AIDS issues.

"San Francisco is a unique place, as we all know," said Thomas J. Coates, PhD, executive director of the UCSF ARI. "It is one place in the world where science, public health, communities, politics, and policies have worked together to provide innovation in science, prevention, and care. We want to work with investigators and public health officials in other parts of the world to help stem the tide of HIV/AIDS in those countries."

Over the past 15 years, UCSF researchers have been involved in a number of AIDS-related activities in Africa, India, Brazil, Peru, Mexico, China, and Vietnam, and the international program will focus on strengthening and building on these efforts, Padian said.

"We will look at AIDS as a global issue, but our emphasis will be on practical applications in developing countries because the populations in these areas have been devastated by HIV in disproportionate numbers to the rest of the world. This is not research for research's sake but a program that is committed to working with our international colleagues, who are experts in their own cultures, on how to stem the HIV/AIDS epidemic in their homelands," she added.

Coates emphasized that the ARI continues its commitment to HIV/AIDS issues at that local, regional, and national levels and that formalizing the international efforts of UCSF AIDS specialists strengthens all ARI programs. "The foundation of the San Francisco program is that we attend to all aspects of HIV/AIDS, from very basic molecular biology to policy sciences and application," he said.

A member of the UCSF faculty since 1988, Padian has developed and directed a number of research studies on HIV and STDs in high-risk populations. She was one of the first investigators to study heterosexual transmission of HIV in the U.S., and findings from her research projects in the 1980s and 90s are considered major works in this field. In the past few years, Padian has collaborated with the University of Zimbabwe on several projects related to female reproductive health and HIV/STD prevention.

In a series of studies, a Zimbabwe-UCSF team is investigating the safety and user acceptance of vaginal microbicides and the female condom. The microbicide studies include two types of gels applied topically that are designed to acidify the vaginal-cervical environment and/or inactivate STD pathogens including HIV.

Preliminary analysis of study results shows these methods, while not acceptable to all women, provide an important alternative to some, according to Padian. The findings are important, she added, because heterosexual transmission of HIV accounts for the majority of new HIV infections in Zimbabwe, as well as worldwide. The use of male and female condoms involves issues of acceptance, cost, availability, and effectiveness that can be politically and culturally sensitive in developing countries, and it is "urgent that more acceptable and affordable female-controlled methods, such as topical microbicides, be made available to women" in order to control HIV infection, she said.

In other research, Padian's team is collaborating with Zimbabwean colleagues on studies on the impact of oral, hormonal contraceptives, and the use of a diaphragm with spermicide on HIV acquisition in women. Both methods, Padian noted, involve critical unanswered public health questions in sub-Saharan Africa where male partners often control sexual activity and decision-making.

According to UNAIDS, a consortium of United Nations agencies, more than 33.5 million people are living with HIV/AIDS worldwide, and 1999 saw 2.6 million deaths from the disease, a higher global total than in any year since the beginning of the epidemic despite antiretroviral therapy, which has staved off deaths in richer countries. Ninety-five percent of the worldwide HIV population lives in the developing world.

This article was prepared by AIDS Weekly editors from staff and other reports.

000501
AW000506


Copyright © 2000 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1990, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.